Literature DB >> 4004418

Regional vasodilating and cardiac effects of nicardipine in anaesthetized open chest dog.

S Bongrani, R Razzetti, P Schiantarelli.   

Abstract

In this study the effects of intravenous nicardipine on the cardiovascular system in anaesthetized open chest dogs were assessed. In the dose range of 3-30 nmol/kg it induced a dose-dependent and long lasting reduction of the vertebral, coronary and femoral vascular resistance. Nicardipine proved to be equipotent, but longer lasting than nifedipine, and about 10 and 100 times more potent than verapamil and papaverine respectively. Unlike papaverine, calcium entry blockers caused a preferential vasodilation of the vertebral and coronary arteries. Hypotension and a reduction of LVSP and dP/dt appeared only at the highest dose tested. However, for both dihydropyridine derivatives, in contrast to verapamil, the cardiodepressant effects were short-lived and resulted less marked for nicardipine than for nifedipine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4004418

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  5 in total

1.  Cardiovascular interaction between sevoflurane and nicardipine in open chest dogs.

Authors:  N Iwatsuki; A Kaise; Y Koga; H Ishii
Journal:  J Anesth       Date:  1988-09-01       Impact factor: 2.078

2.  The hemodynamic properties of amlodipine in anesthetised and conscious dogs: comparison with nitrendipine and influence of beta-adrenergic blockade.

Authors:  M G Dodd; D G Gardiner; A J Carter; M R Sutton; R A Burges
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

Review 3.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

4.  [Calcium antagonists in heart failure?].

Authors:  H Drexler; H Just
Journal:  Klin Wochenschr       Date:  1986-10-15

Review 5.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.